Cargando…

From Structural Studies to HCV Vaccine Design

Hepatitis C virus (HCV) is a serious and growing public health problem despite recent developments of antiviral therapeutics. To achieve global elimination of HCV, an effective cross-genotype vaccine is needed. The failure of previous vaccination trials to elicit an effective cross-reactive immune r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yechezkel, Itai, Law, Mansun, Tzarum, Netanel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147963/ https://www.ncbi.nlm.nih.gov/pubmed/34064532 http://dx.doi.org/10.3390/v13050833

Ejemplares similares

The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein
por: Tzarum, Netanel, et al.
Publicado: (2018)

An alternate conformation of HCV E2 neutralizing face as an additional vaccine target
por: Tzarum, Netanel, et al.
Publicado: (2020)

Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines
por: He, Linling, et al.
Publicado: (2020)

Genetic and structural insights into broad neutralization of hepatitis C virus by human V(H)1-69 antibodies
por: Tzarum, Netanel, et al.
Publicado: (2019)

A structured RNA motif locks Argonaute2:miR-122 onto the 5’ end of the HCV genome
por: Gebert, Luca F. R., et al.
Publicado: (2021)

Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis
por: Gopal, Radhika, et al.
Publicado: (2017)

A Meta-Analysis of the Existing Knowledge of Immunoreactivity against Hepatitis C Virus (HCV)
por: Kim, Yohan, et al.
Publicado: (2012)

RNA Encapsulation Mode and Evolutionary Insights from the Crystal Structure of Emaravirus Nucleoprotein
por: Izhaki-Tavor, Lee S., et al.
Publicado: (2023)

HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development
por: Ströh, Luisa J., et al.
Publicado: (2020)

Therapeutic vaccines in HBV: lessons from HCV
por: Barnes, Eleanor
Publicado: (2015)

Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design
por: Cowton, Vanessa M., et al.
Publicado: (2021)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice
por: Alzua, Garazi Pena, et al.
Publicado: (2023)

Lessons from Nature: Understanding Immunity to HCV to Guide Vaccine Design
por: Freeman, Zachary T., et al.
Publicado: (2016)

Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine
por: Gholizadeh, Monireh, et al.
Publicado: (2015)

Hepatitis C Virus (HCV)–Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design
por: Wrensch, Florian, et al.
Publicado: (2018)

Immunopotentiating and Delivery Systems for HCV Vaccines
por: Andrianov, Alexander K., et al.
Publicado: (2021)

Antibodies against viruses: passive and active immunization
por: Law, Mansun, et al.
Publicado: (2008)

Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding
por: He, Linling, et al.
Publicado: (2015)

Structural and Biophysical Characterization of the HCV E1E2 Heterodimer for Vaccine Development
por: Toth, Eric A., et al.
Publicado: (2021)

Ever closer to a prophylactic vaccine for HCV
por: Swadling, Leo, et al.
Publicado: (2013)

Editorial: Hardware implementation of spike-based neuromorphic computing and its design methodologies
por: Zhang, Lining, et al.
Publicado: (2023)

To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity
por: Schlotthauer, Felicia, et al.
Publicado: (2021)

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A
por: Velázquez-Moctezuma, Rodrigo, et al.
Publicado: (2017)

HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis
por: Medvedev, Regina, et al.
Publicado: (2016)

Synthesis of Vertical Carbon Nanotube Interconnect Structures Using CMOS-Compatible Catalysts
por: Ma, Zichao, et al.
Publicado: (2020)

LncRNAs in HCV Infection and HCV-Related Liver Disease
por: Unfried, Juan P., et al.
Publicado: (2020)

Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition
por: Chen, Duozhi, et al.
Publicado: (2015)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
por: Luxenburger, Hendrik, et al.
Publicado: (2018)

HCV core antigen plays an important role in the fight against HCV as an alternative to HCV‐RNA detection
por: Wang, Yuhan, et al.
Publicado: (2021)

HCV and Lymphoproliferation
por: Zignego, Anna Linda, et al.
Publicado: (2012)

New treatments for HCV: Perspective from Asia
por: Yu, Ming‐Lung, et al.
Publicado: (2015)

Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020
por: Feld, Jordan J., et al.
Publicado: (2021)

Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection
por: Sung, Pil Soo, et al.
Publicado: (2015)

A review on HCV inhibitors: Significance of non-structural polyproteins
por: Ganta, Narayana Murthy, et al.
Publicado: (2019)

Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection
por: Moise, Leonard, et al.
Publicado: (2014)

HBV and HCV Therapy
por: Lampertico, Pietro, et al.
Publicado: (2009)

HCV and immigration in Italy
por: Massimo, Galli, et al.
Publicado: (2018)

Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives
por: Major, Marian E.
Publicado: (2009)

Regulation of gene expression by microRNA in HCV infection and HCV–mediated hepatocellular carcinoma
por: Gupta, Priyanka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pjsupjn1lt1uq8a7kvmtb9n3uc